Infantile Spasms
20
2
2
14
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.0%
1 terminated out of 20 trials
93.3%
+6.8% vs benchmark
35%
7 trials in Phase 3/4
29%
4 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (20)
Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
A Study to Prevent Infantile Spasms Relapse
Open-label Extension to Protocol 1042-0500
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
Genetic Studies in Patients and Families With Infantile Spasms
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
Addition of Pyridoxine to Prednisolone in Infantile Spasms
Epilepsy Phenome/Genome Project
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
Evaluation of Neuroinflammation in Children With Infantile Spasms
Molecular Genetics in Infantile Spasms
Sabril Patient Registry
Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy
Prednisolone in Infantile Spasms- High Dose Versus Usual Dose
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
Use of the Modified Atkins Diet in Infantile Spasms
Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
Metabolic Abnormalities in Children With Epilepsy